Genetic Deficiency of Complement Isoforms C4A or C4B Predicts Improved Survival of Metastatic Renal Cell Carcinoma

Journal of Urology

Volumn 181, Issue 3, 2009, Pages 1028-1034

  Zafar, Ghazal I ^a   Grimm, Elizabeth A ^a   Wei, Wei ^a   Johnson, Marcella M ^a   Ellerhorst, Julie A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

autoimmunity; carcinoma; complement C4; kidney; mortality; renal cell

Indexed keywords

ALPHA INTERFERON; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C4B; GAMMA INTERFERON; HLA ANTIGEN CLASS 2; INTERLEUKIN 2; ISOPROTEIN; TUMOR NECROSIS FACTOR;

ADULT; AGED; ALLELE; ARTICLE; AUTOIMMUNITY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; COMPARATIVE STUDY; COMPLEMENT DEFICIENCY; CONTROLLED STUDY; FEMALE; GENE; GENE AMPLIFICATION; GENE NUMBER; GENE REPLICATION; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC LINKAGE; GENOTYPE; HAPLOTYPE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE GENETICS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RP1 GENE; TNXA GENE;

ADULT; AGED; CARCINOMA, RENAL CELL; COMPLEMENT C4A; COMPLEMENT C4B; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROTEIN ISOFORMS; SURVIVAL RATE;

EID: 59449090701     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2008.11.013     Document Type: Article

References (14)

1. Figlin R.A. Renal cell carcinoma: management of advanced disease. J Urol 161 (1999) 381
2. Franzke A., Peest D., Probst-Kepper M., Buer J., Kirchner G.I., Brabant G., et al. Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer. J Clin Oncol 17 (1999) 529
3. Yang J.C., Hughes M., Kammula U., Royal R., Sherry R.M., Topalian S.L., et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 30 (2007) 825
4. Ellerhorst J.A., Hildebrand W.H., Cavett J.W., Fernandez-Vina M.A., Hodges S., Poindexter N., et al. Heterozygosity or homozygosity for two HLA class II haplotypes predict favorable outcomes for renal cell carcinoma treated with cytokine therapy. J Urol 169 (2003) 2084
5. Blanchong C.A., Chung E.K., Rupert K.L., Yang Y., Yang Z., Zhou B., et al. Genetic, structural and functional diversities of human complement components C4A and C4B and their mouse homologues, Slp and C4. Int Immunopharmacol 1 (2001) 365
6. Isenman D.E. C4. In: Morley B.J., and Walport M.J. (Eds). The Complement FactsBook (2000), Academic Press, San Diego 95-103
7. Yang Y., Chung E.K., Zhou B., Lhotta K., Hebert L.A., Birmingham D.J., et al. The intricate role of complement component C4 in human systemic lupus erythematosus. Curr Dir Autoimmun 7 (2004) 98
8. Gilliam B.E., Wolff A.E., and Moore T.L. Partial C4 deficiency in juvenile idiopathic arthritis patients. J Clin Rheumatol 13 (2007) 256
9. Chung E.K., Yang Y., Rupert K.L., Jones K.N., Rennebohm R.M., Blanchong C.A., et al. Determining the one, two, three, or four long and short loci of human complement C4 in a major histocompatibility complex haplotype encoding C4A or C4B proteins. Am J Hum Genet 71 (2002) 810
10. Lewis M.J., and Botto M. Complement deficiencies in humans and animals: links to autoimmunity. Autoimmunity 39 (2006) 367
11. Prodeus A.P., Goerg S., Shen L.M., Pozdnyakova O.O., Chu L., Alicot A.M., et al. A critical role for complement in maintenance of self-tolerance. Immunity 9 (1998) 721
12. Carroll M.C. A protective role for innate immunity in systemic lupus erythematosus. Nat Rev Immunol 4 (2004) 825
13. Mauff G., Luther B., Schneider P.M., Rittner C., Stradmann-Bellinghausen B., Dawkins R., et al. Reference typing report for complement component C4. Exp Clin Immunogenet 15 (1998) 249
14. Gogas H., Ioannovich J., Dafni U., Stavropoulou-Giokas C., Frangia K., Tsoutsos D., et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354 (2006) 709